issolution testing is a cri t i cal test for measuri n g the pe rfo rm a n ce of a drug prod u ct .The dissolution test is an analytical technique that has underg o n e s i g n i f i ca nt equipment mod i f i cations and improvem e nts spanning the last deca d e.Dissolution has be come an impo rt a nt and widely utilized te s t re ceiving more emphasis wo rl dwide from re g u l ato ry authorities during the last 15 ye a r s.It is a cri ti cal quality co nt rol too l ,and an aid to fo rm u l at i o n d eve l o p m e nt .Dissolution testing measures change on stability,and is used to establish in-vitro in-vivo co rre l ations for some prod u ct s.The dissolution te s t has undergone changes and upd ates as a result of the increased re g u l ato ry inte rest and the pharm ace u t i cal industry's ex a m i n ation of aspe cts of dissolution testing to further improve and understand the te c h n i q u e. This article pre s e nts the curre nt activities re l ate d to dissolution testing in the fo l l owing org a n i z at i o n s or gro u p s :US Ph a rm a co peia (USP),Food and Dru g Ad m i n i s t ration (FDA),Fe d e ration Inte rn at i o n a l e Ph a rm a ceutique (FIP) Dissolution Wo rking Gro u p, Ph a rm a ce u t i cal Re s e a rch and Ma n u f a ct u rers of Am e ri cas (PhRMA) Dissolution Co m m i t tee and PhRMA Ca l i b ration Subco m m i t te e.Pu b l i cat i o n s and we b s i tes such as Dissolution Te c h n o l ogies and the Dissolution Discussion Group will be descri be d. A discussion of new te c h n o l ogy and trends in dissolution testing is included.
USP
Over the last 20 years,USP has been actively involved in setting public dissolution standards that have kept up with changes in technology and are responsive to the concerns of drug manufacturers and the FDA. (1) In 2000,the USP held its Quinquennial meeting. At this five-year meeting the direction of the USP was voted on and set forth through resolutions from the USP convention.USP adopted the following resolutions related to dissolution testing:
• In co n s u l t ation with the FDA,expand on going h a rm o n i z ation with the Eu ro pean and Japanese Ph a rm a co pe i a s,and the Ph a rm a co peias of the Am e ri ca s.
• Assess the feasibility and advisability of developing approaches for the application of the biopharmaceutics principles in conjunction with appropriate dissolution tests to assure equivalent performances of immediate-and modified-release drug products,taking into account their regulatory control.
• Establish training programs to support appropriate use of USP/NF standards and compendial methods.
To support the first resolution,there is an ongoing effort to harmonize the Dissolution <711>,Disintegration <701>,and Drug Release <724> General Chapters with the Japanese Pharmacopeia and European Pharmacopeia.This collaboration is part of the ICH harmonization process and is nearly complete. Aspects of the general chapters, such as adding additional equipment dimensions and specifications,equipment modifications, and allowance of validated sinkers and automated equipment are included in this initiative. Most importantly, however,is the incorporation of the USP Acceptance Criteria.The current debate is over the addition of Stage three testing in the European countries and Britain.
In an initial step toward the second resolution, the new USP Biopharmaceutics Expert Committee has endorsed the adoption of the FDA Biopharmaceutics Classification System (BCS) Guidance. The new guidance on this subject will be put into a new USP General Informational Chapter.
The new USP Biopharmaceutics Expert Committee includes five academicians, four industry representatives, and one member from The third resolution is completed for the area of dissolution.USP now offers a two-day course on dissolution with hands-on training and lectures at the USP headquarters on a monthly basis.
In the area of calibration,the USP has replaced In these guidances the FDA presents the similarity factor (the f 2 calculation).There have been several discussions on this approach for comparing the dissolution profiles of different batches to assess or establish bioequivalence. (3) (4) (5).The Biopharmaceutics Classification System,was presented in several guidances, however the definitive guidance -Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System, shows how this system can use dissolution testing as an alternative to bioequivalence studies.
The FDA appo i nted a task fo rce,the Ge l at i n Capsule Wo rking Gro u p,to study the in vivo effe ct of gelatin capsules that show a slowd own in dissolution due to cro s s -l i n ki n g.The results we re published in the Ph a r m a co peial Fo ru m.( 6 ) Fo l l owing the re co m m e n d ations of the Wo rki n g Gro u p,the USP Dissolution Ge n e ral Ch a p ter <711> was revised to allow for two-tier dissolution te s t i n g. E n zyme can now be added to the dissolution medium and the dissolution test re pe ate d.
The FDA co-sponsors many workshops and conferences on current regulatory issues.The next workshop planned,co-sponsored with AAPS,is in March 2002 on establishing drug product specifications.There will be breakout sessions dealing with several topics,including dissolution and disintegration.
FIP Dissolution Working Group
This group spe a rheaded the writing of the FIP Guidelines for Dissolution Testing of Solid Ora l Prod u ct s.The guideline was published as a joint re po rt of the section for Official Labo rato ries and Medicines Co nt rol Se rv i ces and the section of I n d u s t rial Ph a rmacist of the FIP. (7) The main focus of the FIP Dissolution Wo rki n g Group is to provide a fo rum for discussion of dissolution issues and also provide training for dissolution analys t s.The group has spo n s o red two wo rkshops on dissolution testing of spe c i a l dosage fo rm s.As a result of these wo rk s h o p s, a review paper was pre p a red that discusses re g u l ato ry aspe cts and analytical issues re l ating to s pecial dosage fo rms (see pages 6-11).
The wo rking group has also held two tra i n i n g wo rkshops on dissolution te s t i n g.In 2000,t h e re was an inte rm e d i ate level wo rkshop in Au s t ra l i a and in January of 2001 there was a basic leve l wo rkshop held in India (8).The next basic wo rkshop is planned for two cities in China in May 2002.
PhRMA Dissolution Committee
One major function of this committee was to conduct a collaborative study that determines the ranges for USP Calibrator Tablets.A recent collaborative study includes 20-30 laboratories that perform dissolution tests on the calibrator tablets using both the basket and paddle dissolution apparatus at different speeds.The studies are published in the Pharmacopeial Forum of the USP to inform the scientific community how the range specifications are obtained and show the detailed statistical analysis (9).With the most recent lot of Prednisone Tablets,the USP has managed the collaborative study with cooperation and participation of PhRMA.
This
PhRMA Dissolution Calibration Subcommittee
Within the PhRMA Dissolution Committee is a Dissolution Calibration Subcommittee.This subcommittee's purpose is to examine dissolution apparatus calibration and look for ways to reduce testing without compromising the standards for equipment evaluation.Mechanical calibration was studied thoroughly as an alternative to using USP calibrator tablet testing. (8) The PhRMA Dissolution Calibration Subcommittee is exploring other ways of examining the utility of calibrator testing.A survey to gather historical calibrator data is now available through several websites.
Dissolution Technologies
This publication is published quarterly, providing useful information on dissolution testing. It provides a forum for dissolution analysts to receive and exchange information on various dissolution topics. The Dissolution Technologies website can be accessed at www.dissolutiontech.com.
Dissolution Discussion Group (DDG)
This group has an Internet discussion site at www.dissolution.com.It provides an interactive bulletin board forum on all topics in dissolution testing.The group meets annually where round table discussions are conducted on a variety of topics and issues.Regional meetings are also sponsored in various locations in the US and Update on Dissolution Testing … continued around the world.
New Dissolution Technology
The areas of most recent growth in dissolution testing equipment are fiber optic technology and fully automated dissolution testers.
The use of fiber optic technology as a labor saving feature of testing has been discussed for years.Now there are at least three major vendors selling this equipment in a variety of configurations.Several articles on the application and validation of fiber optics technology and its utility have been published.(11) (12) (13) (14) The fiber optics detection cell is either located in the basket or paddle shaft or as a probe placed directly into the medium.Fiber optic detection avoids the filtering and pumping of sample and permits continuous measurements during the course of the dissolution test.
Automation has become more sophisticated with on-line UV measurement systems that use flow cells for real-time determinations,eliminating fraction collection and separate UV analysis.There are fully automated systems that deaerate and heat medium,fill the vessels with medium,drop tablets,filter and sample the vessel medium,and clean the vessels.
Other labor saving products,such as premixed medium and mobile phase, are now commercially available.Premixed media of all compositions, and in some cases deaerated,is shipped in sealed plastic containers and offers off-the-shelf convenience.
Conclusion
Dissolution testing is continuing to grow and mature as a critical technology to pharmaceutical analysis.The resources for information are abundant and many organizations are actively involved in the improvement and application of the technique.The manufacturers of dissolution equipment are actively developing new and more sophisticated equipment. Worldwide regulatory agencies are relying on the test more and more for relevance to in vivo performance.It is anticipated that dissolution will continue to grow as a meaningful and sophisticated test for the analysis of pharmaceutical dosage forms.
